Drug Overview Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder. Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NF?B, and antigen-induced lung eosinophilia, thereby suppressing inflammation. Vilanterol is a long-acting beta 2 agonist that stimulates intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic-3’,5’-adenosine monophosphate (AMP). Increased levels of cyclic AMP result in the relaxation of bronchial smooth muscles and inhibition of the release of mediators of immediate hypersensitivity from mast cells.
Our reports have been used by over 10K customers, including:
306 pages •
By Global Industry Analysts
• Jul 2022
Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass...
452 pages •
By Global Industry Analysts
• Jul 2022
Abstract: What`s New for 2022? - Global competitiveness and key competitor percentage market shares - Market presence across multiple geographies - Strong/Active/Niche/Trivial - Online interactive peer-to-peer collaborative bespoke updates - Access to our digital archives and MarketGlass...
150 pages •
By Roots Analysis Private Ltd.
• Jun 2022
INTRODUCTION With several blockbuster therapies (such as Humira®, Rituxan®, Lantus®, Avastin®, Herceptin® and Remicade®) and a robust pipeline of product / therapy candidates, the biopharmaceutical market is anticipated to witness significant growth in the next few years. However, it has been established that biologic drug...
Degenerative Disc Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players,...
The global biological safety testing market reached a value of US$ 3.51 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 7.16 Billion by 2027, exhibiting at a CAGR of 12.55% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
The Global Gene Synthesis Market size is expected to reach $5.2 billion by 2027, rising at a market growth of 17.9% CAGR during the forecast period. Gene synthesis is the process of developing or generating artificial genes through scientific processes. In addition, Gene synthesis refers to the process in which genes are developed through...
The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The market growth is attributed to factors such as the increasing prevalence...
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021 Summary According to the recently published report ’Insulin Like Growth Factor I - Drugs In Development, 2021’; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)...
Therapy
Biopharmaceutical
Breast Cancer
Cell Therapy
Targeted Therapy
Chronic Pain
Protein Therapy
World
Cause-Specific Mortality Rate
Drug Approval
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.